ImmuCell Corp. of Portland, Maine, was awarded a $50,000grant from the National Institute of Allergy and InfectiousDiseases to study orally administered antibodies for thetreatment of cryptosporidiosis in AIDS patients.
The project will investigate the potential of clonedCryptosporidium antigens as a vaccine. Infection withCryptosporidium parvum causes severe diarrhea in about 5percent to 10 percent of AIDS patients in the U.S. and 20 to 30percent in Europe and Asia.
ImmuCell's antibody product is in Phase I trials in AIDSpatients in a collaboration with Univax Biologics Inc.
(c) 1997 American Health Consultants. All rights reserved.